Neurofibromatosis type 1 (NF1) is a frequent hereditary disorder. One of the characteristic features of this disease is the development of neurofibromas. Since the NF1 gene is supposed to be a tumour suppressor gene, these neurofibromas should develop upon inactivation of both NF1 alleles. So far, mutation and deletion have been found to be involved in NF1 gene inactivation. However, these inactivating mechanisms explain the development of only a limited fraction of analysed neurofibromas. In this study, we investigated microsatellite instability (MSI) and promoter methylation as potential contributors to NF1 gene inactivation. As site-specific methylation in the NF1 promoter inhibits binding of transcription factors Sp1 and CREB, we studied the methylation status of their binding sites in particular. We analysed 20 neurofibromas and three neurofibrosarcomas, but did not find evidence for microsatellite instability or NF1 promoter methylation in any of the tumours. Thus, our data suggest that both microsatellite instability and promoter methylation are unlikely to be the major causes of NF1 gene inactivation in these tumours.
Introduction
Neurofibromatosis type 1 (NF1) or von Recklinghausen disease is one of the most common hereditary diseases of man. Characteristic features of this autosomal dominant disorder are the development of café-au-lait spots, Lisch nodules on the iris, and of benign dermal or plexiform neurofibromas. 1 The NF1 gene on chromosome arm 17q is supposed to be a tumour suppressor gene, of which, according to Knudson's two-hit model for tumorigenesis, 2 both alleles have to be inactivated for tumour formation to occur. Indeed, inactivation of both NF1 alleles has been demonstrated in four dermal neurofibromas, 3, 4 in three plexiform neurofibromas, [4] [5] [6] and in a neurofibrosarcoma, 7 a malignant peripheral nerve sheath tumour (MPNST) for which NF1 patients are at increased risk. However, mutation and/or deletion of the NF1 gene, the latter often detectable as loss of heterozygosity (LOH), have only been reported for a limited fraction of the analysed neurofibromas. LOH rates range from 0 to 25-35% for dermal neurofibromas 5, 6, 8, 9 and from 20 to 60% for plexiform neurofibromas, 4, 5 whereas mutations in the NF1 gene have only been found in a few tumours. 3, 4, 6 Cases for which no LOH or mutation as inactivating mechanism could be demonstrated may be explained by the presence of subtle deletions, escaping detection by LOH, or by inadequate mutation detecting systems. We wondered whether other means of NF1 gene inactivation, especially microsatellite instability (MSI) and promoter methylation, might contribute to inactivation of the NF1 gene in neurofibromas and neurofibrosarcomas. MSI reflects genomic instability, which is normally caused by loss of mismatch repair function. Genomic instability could, among other targets, disrupt the NF1 gene. 10 
Materials and methods

Patients and tumour samples
Tumour and corresponding blood samples were obtained from 23 unrelated patients. Genomic DNAs were isolated using standard procedures. Type and location of the tumour and NF1 status of the patient are given in Table 1 . Individuals without NF1 were not reported to be affected by other diseases.
LOH
The LOH status of the NF1 gene region was determined by analysing the following markers:
and IVS27AC28.4 are located in intron 27 of the NF1 gene, and marker IVS38GT53.0 is in intron 38 of the NF1 gene. For each tumour, the LOH status was derived from at least two informative markers. Primer sequences and PCR conditions for these markers were taken from the Genome Database (http://www.gdb.org). PCR was performed as described previously. 18 LOH was determined by visual inspection of autoradiographs. LOH in neurofibromas is never complete due to variable contribution of cells without LOH. Therefore, in tumours with less significant visual loss of one allele, LOH was additionally assessed by laser scanning densitometry (Phosphorimager, Molecular Dynamics, Sunnyvale, CA, USA).
Microsatellite instability (MSI)
Tumour and corresponding blood samples were subjected to PCR using microsatellite markers BAT25, BAT26, BAT40, D2S123, D5S346, and D17S250 from the reference panel for 20 PCR products were analysed on 6% polyacrylamide sequencing gels.
Sequencing of the antisense strand of the Sp1 site
The region harbouring the Sp1 site was PCR-amplified from bisulfite modified tumour DNA. To amplify the antisense strand, the following primers were used: 5'-CTA-AAA-AAA-AAA-CTA-ACC-CCA-AAA-3' and 5'-GGT-TGG-GAA-AGG-GGA-3', corresponding to, respectively, nucleotides -232 to -209 and 92 to 78 in the NF1 promoter sequence. 17 The resulting 300 bp products were excised from polyacrylamide gels and extracted by incubation at 65°C for 15 min in 300 µl of 10 mM Tris-HCl, pH 7.6, 1 mM EDTA. After purification using Spin-X columns (Costar, Acton, MA, USA), DNAs were ethanol precipitated and dissolved in 25 µl H 2 O. A second PCR was performed on 50 ng of purified DNA, using the same primers. The resulting PCR products were sequenced on an Applied Biosystems Model 377 automated sequencer using the Big Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer, Foster City, CA, USA). Sequencing was performed in triplicate using the reverse primer.
Methylation-specific PCR (MSP)
The methylation status of the strand of the CRE site in the NF1 promoter was determined by MSP following sodium bisulfite treatment of 2 µg of DNA. 21 Primers used for unmethylated reactions of the CRE motif were: 5'-TGT-TTG-TTA-GAT-GGT-TTA-GAG-GAG-TTA-GAT-GAT-3' (sense) and 5'-AAA-AAC-AAA-AAA-AAA-AAC-AAC-CTA-CCA-CA-3' (antisense), and for methylated reactions: 5'-CGT-TAG-ACG-GTT-TAG-AGG-AGT-TAG-ATG-AC-3' (sense) and 5'-AAA-AAA-AAA-ACG-ACC-TAC-CGC-G-3' (antisense). PCR reactions were hot-started at 95°C for 5 min before the addition of 1.25 units of Taq polymerase. Amplification of 50 ng of bisulfitetreated DNA was performed by 35 cycles (30 s at 95°C, 30 s at 62°C, and 30 s at 72°C), followed by a final 5-min extension at 72°C. All PCRs included no DNA control as well as positive controls for both unmethylated and methylated alleles. For the latter, human placental DNA was treated with excess SssI methyltransferase (New England Biolabs, Beverly, MA, USA), according to the manufacturer's protocol. PCR products were directly loaded on to nondenaturing 8% polyacrylamide gels, and visualised under UV illumination after ethidium bromide staining.
Results
We analysed 20 neurofibromas and three neurofibrosarcomas from 23 patients for the presence of LOH in the NF1 gene region and for MSI. Furthermore, we determined the methylation status of the Sp1 binding site and the CRE site near the Table 1 , 17 tumours were from NF1 patients. LOH for the NF1 gene region was detected in five of 20 neurofibromas (25%) and in the three neurofibrosarcomas (Table 1 and Figure 1 ). Due to variable contribution of cell types without LOH in the neurofibromas, allele loss was never found to be complete (Figure 2) . The tumours showed LOH for all intragenic markers, except for tumour 444 in which the NF1 gene seems to be only partially deleted.
The presence of MSI in the tumours was determined by analysis of mononucleotide repeat markers BAT25, BAT26, and BAT40, and dinucleotide repeat microsatellite markers D2S123, D5S346, and D17S250. Corresponding leukocyte DNAs were used as negative control, whereas DNA from a MSI-positive duodenum carcinoma from a patient with MuirTorre syndrome was used as positive control. We did not detect MSI in any of the tumours. Representative examples, showing presence of MSI for marker BAT26 in the duodenum carcinoma but absence of MSI in the neurofibromas, are given in Figure 3 .
By in vitro studies, it has been demonstrated that methylation of the first two cytosines in the antisense strand of the Sp1 recognition sequence nearby the transcription start site impedes binding of the Sp1 protein (see Figure 4) . 16 To evaluate the methylation status of these cytosine residues, we treated each tumour DNA with sodium bisulfite and sequenced the antisense strand of the Sp1 motif in every tumour. In Figure 5 , the sequencing electrophoretogram in 5'-3' orientation for the Sp1 site in neurofibroma 443 is shown. The two cytosines have been converted into thymidines (marked by arrows), suggesting that in this tumour these cytosines were unmethylated. Figure 5 is representative Figure 3 Determination of MSI in neurofibromas using microsatellite marker BAT26. Tumour (T) DNA and corresponding blood (B) DNA was subjected to PCR using BAT26-specific primers. PCR products were analysed on 6% polyacrylamide gels; + : duodenum carcinoma with known MSI from a patient suffering from Muir-Torre syndrome; -: no DNA. Case numbers of tumours are indicated. for all tumours: we did not detect any methylation of the two cytosine residues in our tumours. Mancini et al 16 have shown that in vitro binding of CREB is inhibited by cytosine methylation of the CpG dinucleotide in the CRE motif. To assess its methylation status in the tumours, we performed methylation-specific PCR (MSP), using a forward primer that ends in the CpG dinucleotide (see Figure 4) . Considering the variable contribution of nontumour cells to the tumour tissues, we first checked whether MSP under the conditions applied was sensitive enough to detect methylation. This was performed by gradually diluting in vitro methylated DNA with unmethylated DNA. As shown in Figure 6 , methylation of the CRE site is easily detectable under conditions in which the contribution of methylated DNA is only 5%. Subsequently, we studied the methylation status of the CRE site in all tumours. However, for none of them methylation was found ( Figure 7 ).
Discussion
We detected LOH of the NF1 gene region in five of 20 neurofibromas and in the three neurofibrosarcomas (Table 1 and Figures 1 and 2 ). All tumours showing LOH were from patients with NF1, who are assumed to carry one constitutively inactivated NF1 allele. Assuming that the wild type NF1 was lost by LOH, the development of these tumours may be explained by Knudson's two-hit model for tumorigenesis. 2 At least one hit, a germ line mutation, is supposed to be present in the tumours of the remaining NF1 patients.
In the other tumours, no hit was detected. In these cases, besides subtle deletions escaping detection by LOH or point Hypermethylation of the promoter region may inactivate the NF1 gene by abolishing its expression, as has been shown for several other tumour suppressor genes. [13] [14] [15] In addition, the data of Mancini et al 16 suggest that in vitro binding of the transcription factors Sp1 and CREB is inhibited by methylation of specific cytosine residues in their respective recognition sequences in the NF1 promoter region. In the tumours we examined, there was no indication for methylation of the two cytosines in the antisense strand of the Sp1 site or for cytosine methylation in the CpG dinucleotide of the CRE site ( Figures 5 and 7) . Moreover, the methylation-specific PCR (MSP) that was used for examination of the CpG in the CRE site additionally excluded hypermethylation of the analysed region.
In conclusion, our data suggest that MSI and promoter methylation are unlikely to be involved in NF1 gene inactivation in neurofibromas. 
